GlassScriptPhysician profile
David Shuchih Chu
NPI 1144260019
$234,332.79
in general payments reported to CMS, 2019-2025
33 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $5,784 · 2021: $1,360 · 2022: $38K · 2023: $12K · 2024: $45K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Food and Beverage: $9,710 · Travel and Lodging: $8,494 · Consulting Fee: $5,975 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,335.00 |
| Food and Beverage | $9,710.00 |
| Travel and Lodging | $8,494.24 |
| Consulting Fee | $5,975.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $143,526.40 | 2020-2025 | Acthar |
| Bausch & Lomb Americas INC. | $47,261.20 | 2022-2025 | Xipere, Miebo, Xiidra |
| Mallinckrodt Enterprises LLC | $14,824.19 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $6,529.10 | 2019-2021 | |
| Dompe US, INC. | $5,439.61 | 2019-2025 | Oxervate |
| Harrow Eye, LLC | $3,882.75 | 2024-2025 | Triesence, Vevye |
| Abbvie INC. | $3,881.49 | 2020-2025 | Durysta, Lumigan |
| Sun Pharmaceutical Industries INC. | $1,501.85 | 2019-2025 | Cequa |
| Sight Sciences, INC. | $813.99 | 2019-2025 | Sion Surgical Instrument, Omni Surgical System |
| Allergan, INC. | $673.97 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $641.14 | 2022-2025 | Purified Cortrophin Gel, Iluvien |
| Eyepoint US, INC. | $625.62 | 2022-2023 | |
| Oyster Point Pharma, INC. | $550.63 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $507.43 | 2024-2025 | Xdemvy |
| Rxsight INC | $455.91 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $390.32 | 2022-2025 | Rocklatan, Clareon, Tryptyr |
| Novartis Pharmaceuticals Corporation | $381.92 | 2019-2022 | |
| Ocular Therapeutix, INC. | $338.03 | 2020-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $289.04 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $277.07 | 2019-2022 | |
| Horizon Therapeutics Plc | $246.39 | 2022-2023 | Tepezza |
| Glaukos Corporation | $242.56 | 2024-2025 | Idose, Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $209.36 | 2020-2022 | |
| Rayner Intraocular Lenses Limited | $163.51 | 2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Alimera Sciences, INC. | $149.26 | 2023-2024 | Iluvien, Yutiq |
| Samsara Vision | $138.92 | 2025 | Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) |
| New World Medical,INC. | $132.60 | 2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Amgen INC. | $92.65 | 2024-2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $84.79 | 2019-2022 | |
| Biotissue Holdings INC. | $42.61 | 2022 | |
| Beaver-Visitec International, INC. | $25.98 | 2021 | |
| Shire North American Group INC | $12.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.